Cargando…
Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes
BACKGROUND: The prevalence of diabetes is increasing in all industrialized countries and its prevention has become a public health priority. However, the predictors of diabetes risk are insufficiently understood. We evaluated, whether 31 novel biomarkers could help to predict the risk of incident di...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852424/ https://www.ncbi.nlm.nih.gov/pubmed/20396381 http://dx.doi.org/10.1371/journal.pone.0010100 |
_version_ | 1782179942561218560 |
---|---|
author | Salomaa, Veikko Havulinna, Aki Saarela, Olli Zeller, Tanja Jousilahti, Pekka Jula, Antti Muenzel, Thomas Aromaa, Arpo Evans, Alun Kuulasmaa, Kari Blankenberg, Stefan |
author_facet | Salomaa, Veikko Havulinna, Aki Saarela, Olli Zeller, Tanja Jousilahti, Pekka Jula, Antti Muenzel, Thomas Aromaa, Arpo Evans, Alun Kuulasmaa, Kari Blankenberg, Stefan |
author_sort | Salomaa, Veikko |
collection | PubMed |
description | BACKGROUND: The prevalence of diabetes is increasing in all industrialized countries and its prevention has become a public health priority. However, the predictors of diabetes risk are insufficiently understood. We evaluated, whether 31 novel biomarkers could help to predict the risk of incident diabetes. METHODS AND FINDINGS: The biomarkers were evaluated primarily in the FINRISK97 cohort (n = 7,827; 417 cases of clinically incident diabetes during the follow-up). The findings were replicated in the Health 2000 cohort (n = 4,977; 179 cases of clinically incident diabetes during the follow-up). We used Cox proportional hazards models to calculate the relative risk of diabetes, after adjusting for the classic risk factors, separately for each biomarker. Next, we assessed the discriminatory ability of single biomarkers using receiver operating characteristic curves and C-statistics, integrated discrimination improvement (IDI) and net reclassification improvement (NRI). Finally, we derived a biomarker score in the FINRISK97 cohort and validated it in the Health 2000 cohort. A score consisting of adiponectin, apolipoprotein B, C-reactive protein and ferritin almost doubled the relative risk of diabetes in the validation cohort (HR per one standard deviation increase 1.88, p = 2.8 e-5). It also improved discrimination of the model (IDI = 0.0149, p<0.0001) and reclassification of diabetes risk (NRI = 11.8%, p = 0.006). Gender-specific analyses suggested that the best score differed between men and women. Among men, the best results were obtained with the score of four biomarkers: adiponectin, apolipoprotein B, ferritin and interleukin-1 receptor antagonist, which gave an NRI of 25.4% (p<0.0001). Among women, the best score included adiponectin, apolipoprotein B, C-reactive protein and insulin. It gave an NRI of 13.6% (p = 0.041). CONCLUSIONS: We identified novel biomarkers that were associated with the risk of clinically incident diabetes over and above the classic risk factors. This gives new insights into the pathogenesis of diabetes and may help with targeting prevention and treatment. |
format | Text |
id | pubmed-2852424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-28524242010-04-14 Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes Salomaa, Veikko Havulinna, Aki Saarela, Olli Zeller, Tanja Jousilahti, Pekka Jula, Antti Muenzel, Thomas Aromaa, Arpo Evans, Alun Kuulasmaa, Kari Blankenberg, Stefan PLoS One Research Article BACKGROUND: The prevalence of diabetes is increasing in all industrialized countries and its prevention has become a public health priority. However, the predictors of diabetes risk are insufficiently understood. We evaluated, whether 31 novel biomarkers could help to predict the risk of incident diabetes. METHODS AND FINDINGS: The biomarkers were evaluated primarily in the FINRISK97 cohort (n = 7,827; 417 cases of clinically incident diabetes during the follow-up). The findings were replicated in the Health 2000 cohort (n = 4,977; 179 cases of clinically incident diabetes during the follow-up). We used Cox proportional hazards models to calculate the relative risk of diabetes, after adjusting for the classic risk factors, separately for each biomarker. Next, we assessed the discriminatory ability of single biomarkers using receiver operating characteristic curves and C-statistics, integrated discrimination improvement (IDI) and net reclassification improvement (NRI). Finally, we derived a biomarker score in the FINRISK97 cohort and validated it in the Health 2000 cohort. A score consisting of adiponectin, apolipoprotein B, C-reactive protein and ferritin almost doubled the relative risk of diabetes in the validation cohort (HR per one standard deviation increase 1.88, p = 2.8 e-5). It also improved discrimination of the model (IDI = 0.0149, p<0.0001) and reclassification of diabetes risk (NRI = 11.8%, p = 0.006). Gender-specific analyses suggested that the best score differed between men and women. Among men, the best results were obtained with the score of four biomarkers: adiponectin, apolipoprotein B, ferritin and interleukin-1 receptor antagonist, which gave an NRI of 25.4% (p<0.0001). Among women, the best score included adiponectin, apolipoprotein B, C-reactive protein and insulin. It gave an NRI of 13.6% (p = 0.041). CONCLUSIONS: We identified novel biomarkers that were associated with the risk of clinically incident diabetes over and above the classic risk factors. This gives new insights into the pathogenesis of diabetes and may help with targeting prevention and treatment. Public Library of Science 2010-04-09 /pmc/articles/PMC2852424/ /pubmed/20396381 http://dx.doi.org/10.1371/journal.pone.0010100 Text en Salomaa et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Salomaa, Veikko Havulinna, Aki Saarela, Olli Zeller, Tanja Jousilahti, Pekka Jula, Antti Muenzel, Thomas Aromaa, Arpo Evans, Alun Kuulasmaa, Kari Blankenberg, Stefan Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes |
title | Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes |
title_full | Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes |
title_fullStr | Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes |
title_full_unstemmed | Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes |
title_short | Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes |
title_sort | thirty-one novel biomarkers as predictors for clinically incident diabetes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852424/ https://www.ncbi.nlm.nih.gov/pubmed/20396381 http://dx.doi.org/10.1371/journal.pone.0010100 |
work_keys_str_mv | AT salomaaveikko thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes AT havulinnaaki thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes AT saarelaolli thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes AT zellertanja thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes AT jousilahtipekka thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes AT julaantti thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes AT muenzelthomas thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes AT aromaaarpo thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes AT evansalun thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes AT kuulasmaakari thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes AT blankenbergstefan thirtyonenovelbiomarkersaspredictorsforclinicallyincidentdiabetes |